WHO WE ARE
WHAT WE DO
WHO WE WORK WITH
Aduhelm, a revolutionary approval; mapping the road to the clinic
The 'what' that matters - questions worth asking
Telehealth: Tackling Evolving Competitive Landscapes in Response to a Megatrend
Is Pre-Hospital Administration the Future for Antiplatelet Therapies?
15 Years of Biosimilars: Lessons Learnt and What’s Next
Have ‘smart’ devices arrived in healthcare? The emergence of digitally connected combination products
China Market Access: Opportunity or Obstacle?
Why war games are not the answer to understanding markets - Part Two
The rise of real-world evidence in the pharmaceutical industry
A view through the weeds: Where do we stand on medical cannabis
Why war games are not the answer to understanding markets - Part One
Review: Competitive Intelligence in Pharma and Life Science Event
A Hidden Gen: The Billion Dollar US Generic Injectables Market
Synthetic control arms – use of RWE in clinical trials
Virtual Conferences: A Year in Review and Future Direction
The war on vaccines in a post-COVID world
Part II-Should Your Strategy be a Destination or a Journey
Why 2021 Will Be A Fiercely Competitive Year In The Human Growth Hormone (hGH) Market
Part I-Should Your Strategy Be A Destination Or A Journey?
Unlocking the Opportunity in Axial Spondyloarthritis - Treating the Visible and the Invisible
Could targeting lysosomal dysfunction be the key to treating Parkinson’s disease?
From cholesterol to COVID-19: RNA therapeutics as an emerging treatment approach
Could CDK4/6 inhibitors be established in early-stage HR+ breast cancer?
Cancer Cachexia – no time to waste
The US Biosimilar Landscape is Heating Up
The Gene Therapy Revolution Has Arrived. But What’s Next?
Managing cancer patients during the COVID-19 pandemic
COVID-19: Dissecting the therapeutic and vaccine landscape: Volume II
Hidden opportunity in a time of crisis: Rheumatology’s assets at the COVID-19 frontline
COVID-19: Dissecting the therapeutic and vaccine landscape: Volume I
The Show Must Go On: Virtual conferences and primary insights
Nexletol and Nexlizet approvals: a heart-warming price in a space defeated with pricing battles?
Tumor Mutational Burden: end of the road or an uphill battle for acceptance as an immuno-oncology biomarker?
Will PSMA-targeting diagnostics and therapeutics revolutionize Prostate Cancer care?
CTAD Impressions: Is there finally going to be a disease modifying therapy approved for Alzheimer’s?
Rapid Approvals & Innovative Approaches, But Which Sickle Cell Therapies Will Offer Real Benefits?
Key Insights from ESMO 2019
Top tips for managing a drug franchise in a competitive therapy area
Findacure Rare Disease Showcase
Bio Asia Taiwan 2019 Highlights